Sector News

Cancer drugmaker Tesaro weighs its options as wannabe buyers come running

February 9, 2017
Life sciences

Industry watchers have been predicting that cancer drugmaker Tesaro would generate M&A buzz. After all, growth-starved Big Pharma players have proven willing to shell out big bucks for prime oncology targets.

And now it has.

The Massachusetts biotech reportedly has attracted takeover interest from a slew of companies eyeing its potential blockbuster niraparib, according to unnamed sources cited by Reuters. Tesaro is discussing its options with investment banks, including Citigroup, though it’s not actually working toward a sale, the sources say.

The reason? The sizeable gap between bid and ask: Tesaro values itself at a much higher price than wannabe buyers currently do. So, for now, Tesaro is getting strategic advice, including tactics for handling its suitors.

That’s not to say the company wouldn’t sell, period. Clinical trial data set to read out this year on PARP prospect niraparib might help bring the parties closer together on price. The up-and-comer has already posted progression-free survival benefits larger than ever before seen in recurrent ovarian cancer, and EvaluatePharma forecast the drug would rake in $1.9 billion in 2022 sales.

The buyer interest is no surprise, considering the prices Big Pharma has paid over the last couple years to add drugs in the fast-growing cancer field. AbbVie, for one, forked over $21 billion for access to a piece of blood-cancer star Imbruvica, while Pfizer coughed up $14 billion for Medivation, maker of fellow PARP candidate talazoparib.

And while Pfizer may have locked up its PARP player with that Medivation buy, plenty of rival bidders lost out. Gilead Sciences was said to be one of them, and Guggenheim analysts last year predicted the California-based Big Biotech could find Tesaro enticing. Earlier this week, Gilead CEO John Milligan conceded that the company would need acquisitions to fuel growth as its hep C standouts plummet.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.